EC
TCRX icon

EntryPoint Capital’s TScan Therapeutics TCRX Stock Holding History

EntryPoint Capital’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-20,620
Closed -$103K – 956
2024
Q3 		$103K Buy
+20,620
New +$124K 0.06% 554

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
CC
Checkpoint Capital San Francisco, California $279M AUM 45.74% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return

EntryPoint Capital's TCRX Position: Q4 2024 in Review

EntryPoint Capital sold out of TScan Therapeutics (TCRX) in Q4 2024, closing a stake of 20,620 shares — an estimated $103K sold.

EntryPoint Capital first reported a position in TCRX in Q3 2024 and held it in 1 quarter. The position peaked at $103K in Q3 2024. 89 funds tracked by Wall St. Rank hold TCRX as of Q4 2024.

  • EntryPoint Capital reported no remaining TScan Therapeutics position as of Q4 2024 after selling out during the quarter.
  • EntryPoint Capital sold 20,620 TScan Therapeutics shares in Q4 2024, an estimated $103K.
  • EntryPoint Capital first reported a position in TScan Therapeutics in Q3 2024 and held it in 1 quarter.
  • EntryPoint Capital's TScan Therapeutics position peaked at $103K in Q3 2024.
  • 89 funds tracked by Wall St. Rank held TScan Therapeutics as of Q4 2024.

Based on EntryPoint Capital's 13F filing for Q4 2024, filed 11 Feb 2025.